Pacira BioSciences, Inc. (PCRX), headquartered in Parsippany, New Jersey, is a leading provider of non-opioid pain management and regenerative health solutions worldwide. The biopharmaceutical company focuses its research, development, and commercialization efforts on providing alternatives to common opioid medications for post-surgical care.
The company is publicly traded on the NASDAQ under the symbol "PCRX" and is most well-known for its flagship product, EXPAREL. EXPAREL (bupivacaine liposome injectable suspension) is an innovative non-opioid medication that provides long-lasting pain relief to patients undergoing surgery. EXPAREL works by numbing the area around the surgical site and providing pain relief for up to 72 hours post-surgery, which is typically when post-surgical pain is at its peak. This significantly decreases, if not eliminates, the need for opioid medications post-surgery, playing a significant role in the fight against the ongoing opioid crisis.
In addition to EXPAREL, Pacira BioSciences has also broadened its product offerings through organic growth and strategic acquisitions, which include the iovera° system, a handheld device for cryoanalgesia, or nerve blocking through targeted freezing. This unique product provides immediate, sustained relief for up to 90 days, offering yet another effective alternative to opioids.
The vision and mission of Pacira BioSciences align with the global need to proactively address the opioid crisis by providing safer, effective alternatives to manage pain. This mission seems even more important considering the current situation where over-prescription of opioids has led to a serious health issue.
Pacira BioSciences' business strategy also includes establishing strong collaborations and partnerships with other healthcare and pharmaceutical companies to extend the reach of their products. By doing so, they make a more significant impact in the medical field, improving patient outcomes and contributing to sustainable healthcare.
The company demonstrates consistent growth and innovation, continually investing in research and development initiatives to ensure they remain at the forefront of non-opioid pain management advancements.
In summary, Pacira BioSciences, Inc. is not just a pharmaceutical company; it is a strong advocate for change in the healthcare industry. Through its commitment to providing non-opioid alternatives for pain management, it makes a significant contribution to the global efforts to combat the opioid crisis. With a clear vision, innovative products, and a strong dedication to improve patient outcomes, Pacira BioSciences is blazing a trail in non-opioid pain management.